BioCentury | Nov 19, 2020
Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

...CEO of Sanofi (Euronext:SAN; NASDAQ:SNY), onetime FDA Commissioner Mark McClellan and Kim Popovits, chairman, president and CEO of Genomic Health Inc....
BioCentury | Oct 28, 2020
Deals

Thrive takeout could herald consolidation trend for early cancer detection companies

...tests to guide decisions throughout the continuum of patient care. In 2019, Exact Sciences acquired Genomic Health Inc....
BioCentury | Apr 11, 2020
Management Tracks

Harpal Kumar named president of Grail Europe; plus Notable, Oncoceutics, ReAlta, Parker Institute

...System. Parker Institute for Cancer Immunotherapy hired Frederic Pla as COO. He was COO of Genomic Health Inc....
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...joined as chief commercial officer in September. Newmark was senior director of medical affairs at Genomic Health Inc....
BioCentury | Nov 23, 2019
Product Development

New reimbursement models are coming to cancer diagnostics

...of population health sciences at Duke University School of Medicine. Two cancer diagnostic companies -- Genomic Health Inc....
...tumor biomarker tests have already gained increased coverage by conducting prospective trials demonstrating clinical utility. Genomic Health Inc....
...for reimbursement that could encourage investment and speed development.” Steven Shak, Genomic Health In June 2018, Genomic Health...
BioCentury | Jul 30, 2019
Company News

How $2.8B Genomic Health deal catapults Exact beyond Cologuard

...its international reach, its position with payers and its sales force, Exact Sciences is acquiring Genomic Health...
...NASDAQ:EXAS), whose revenues have long been tied to its lone marketed colorectal cancer screen, Cologuard. Genomic Health Inc....
...$1.6 billion in 2020 and produce cost synergies of about $25 million within three years. Genomic Health...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

...NASDAQ:BMRN) 8/1 Post -$0.10 -$0.09 11% Emergent BioSolutions Inc. (NYSE:EBS) 8/1 Post $0.17 $1.07 -84% Genomic Health Inc....
BioCentury | May 3, 2019
Finance

Earnings on deck

...NASDAQ:MYL) 5/7 Pre $0.79 $0.96 -18% Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) 5/7 Pre $5.46 $4.67 17% Genomic Health Inc....
BioCentury | Nov 9, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

...was down $24 (15%) to $140.41 after reporting weaker than expected sales, while diagnostic company Genomic Health Inc....
...consensus estimates of $3.32. R&D expense of $46.6 million was $8.5 million below Street expectations. Genomic Health...
...The number of Oncotype tests delivered in the quarter was 34,810, up 10% from 3Q17. Genomic Health...
BioCentury | Nov 7, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

...was down $24 (15%) to $140.41 after reporting weaker than expected sales, while diagnostic company Genomic Health Inc....
...consensus estimates of $3.32. R&D expense of $46.6 million was $8.5 million below Street expectations. Genomic Health...
...The number of Oncotype tests delivered in the quarter was 34,810, up 10% from 3Q17. Genomic Health...
Items per page:
1 - 10 of 220
BioCentury | Nov 19, 2020
Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

...CEO of Sanofi (Euronext:SAN; NASDAQ:SNY), onetime FDA Commissioner Mark McClellan and Kim Popovits, chairman, president and CEO of Genomic Health Inc....
BioCentury | Oct 28, 2020
Deals

Thrive takeout could herald consolidation trend for early cancer detection companies

...tests to guide decisions throughout the continuum of patient care. In 2019, Exact Sciences acquired Genomic Health Inc....
BioCentury | Apr 11, 2020
Management Tracks

Harpal Kumar named president of Grail Europe; plus Notable, Oncoceutics, ReAlta, Parker Institute

...System. Parker Institute for Cancer Immunotherapy hired Frederic Pla as COO. He was COO of Genomic Health Inc....
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...joined as chief commercial officer in September. Newmark was senior director of medical affairs at Genomic Health Inc....
BioCentury | Nov 23, 2019
Product Development

New reimbursement models are coming to cancer diagnostics

...of population health sciences at Duke University School of Medicine. Two cancer diagnostic companies -- Genomic Health Inc....
...tumor biomarker tests have already gained increased coverage by conducting prospective trials demonstrating clinical utility. Genomic Health Inc....
...for reimbursement that could encourage investment and speed development.” Steven Shak, Genomic Health In June 2018, Genomic Health...
BioCentury | Jul 30, 2019
Company News

How $2.8B Genomic Health deal catapults Exact beyond Cologuard

...its international reach, its position with payers and its sales force, Exact Sciences is acquiring Genomic Health...
...NASDAQ:EXAS), whose revenues have long been tied to its lone marketed colorectal cancer screen, Cologuard. Genomic Health Inc....
...$1.6 billion in 2020 and produce cost synergies of about $25 million within three years. Genomic Health...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

...NASDAQ:BMRN) 8/1 Post -$0.10 -$0.09 11% Emergent BioSolutions Inc. (NYSE:EBS) 8/1 Post $0.17 $1.07 -84% Genomic Health Inc....
BioCentury | May 3, 2019
Finance

Earnings on deck

...NASDAQ:MYL) 5/7 Pre $0.79 $0.96 -18% Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) 5/7 Pre $5.46 $4.67 17% Genomic Health Inc....
BioCentury | Nov 9, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

...was down $24 (15%) to $140.41 after reporting weaker than expected sales, while diagnostic company Genomic Health Inc....
...consensus estimates of $3.32. R&D expense of $46.6 million was $8.5 million below Street expectations. Genomic Health...
...The number of Oncotype tests delivered in the quarter was 34,810, up 10% from 3Q17. Genomic Health...
BioCentury | Nov 7, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

...was down $24 (15%) to $140.41 after reporting weaker than expected sales, while diagnostic company Genomic Health Inc....
...consensus estimates of $3.32. R&D expense of $46.6 million was $8.5 million below Street expectations. Genomic Health...
...The number of Oncotype tests delivered in the quarter was 34,810, up 10% from 3Q17. Genomic Health...
Items per page:
1 - 10 of 220